Mostrar el registro sencillo del ítem

dc.contributor.authorPuentes Pardo, José David 
dc.contributor.authorMoreno SanJuan, Sara
dc.contributor.authorCasado, Jorge
dc.contributor.authorEscudero Feliú, Julia
dc.contributor.authorLópez Pérez, David 
dc.contributor.authorSánchez-Uceta, Paula
dc.contributor.authorGonzález Novoa, Paula
dc.contributor.authorGálvez Peralta, Julio Juan 
dc.contributor.authorCarazo, Ángel
dc.contributor.authorLeón, Josefa
dc.date.accessioned2023-05-04T08:42:53Z
dc.date.available2023-05-04T08:42:53Z
dc.date.issued2023-03-01
dc.identifier.citationPuentes-Pardo, J.D.; Moreno-SanJuan, S.; Casado, J.; Escudero-Feliu, J.; López-Pérez, D.; Sánchez-Uceta, P.; González-Novoa, P.; Gálvez, J.; Carazo, Á.; León, J. PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53. Int. J. Mol. Sci. 2023, 24, 4787. [https://doi.org/10.3390/ijms24054787]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/81326
dc.description.abstractPoly(ADP-ribose) polymerase-1 (PARP-1) is a protein involved in multiple physiological processes. Elevated PARP-1 expression has been found in several tumours, being associated with stemness and tumorigenesis. In colorectal cancer (CRC), some controversy among studies has been described. In this study, we analysed the expression of PARP-1 and cancer stem cell (CSC) markers in CRC patients with different p53 status. In addition, we used an in vitro model to evaluate the influence of PARP-1 in CSC phenotype regarding p53. In CRC patients, PARP-1 expression correlated with the differentiation grade, but this association was only maintained for tumours harbouring wild-type p53. Additionally, in those tumours, PARP-1 and CSC markers were positively correlated. In mutated p53 tumours, no associations were found, but PARP-1 was an independent factor for survival. According to our in vitro model, PARP-1 regulates CSC phenotype depending on p53 status. PARP-1 overexpression in a wild type p53 context increases CSC markers and sphere forming ability. By contrast, those features were reduced in mutated p53 cells. These results could implicate that patients with elevated PARP-1 expression and wild type p53 could benefit from PARP-1 inhibition therapies, meanwhile it could have adverse effects for those carrying mutated p53 tumours.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III FEDER (PI18/01947).es_ES
dc.description.sponsorshipJ.L. was supported by the Nicolás Monardes Program from the Andalusian Health Service (C-0033-2015). J.D.P.-Pes_ES
dc.description.sponsorshipJ.D.P.-P. is funded by a FPU2019 fellowship (FPU190/02269) from the Ministerio de Universidades (Spain).es_ES
dc.language.isoenges_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectColorectal canceres_ES
dc.subjectPARP-1es_ES
dc.subjectCancer stem cellses_ES
dc.subjectP53es_ES
dc.titlePARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/ijms24054787]
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional